J&J Seeks Approval of Combination Diabetes Pill

A subsidiary of Johnson & Johnson (NYSE: JNJ  ) has filed a New Drug Application to the Food and Drug Administration for a combination treatment for type 2 diabetes, according to a company press release.

The treatment is a combination of an experimental medication, canagliflozin, and an established drug, metformin. Combined in a pill, the treatment is intended for patients with type 2 diabetes. This is a form of the disease in which either the body doesn't respond correctly to insulin or doesn't produce enough of the substance.

The new drug has been developed by Johnson & Johnson's Janssen Research and Development subsidiary.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2151366, ~/Articles/ArticleHandler.aspx, 10/25/2014 5:10:29 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement